Schroeder J T, Schleimer R P, Lichtenstein L M, Kreutner W
The Johns Hopkins Asthma and Allergy Center, Department of Medicine, Division of Clinical Immunology, Johns Hopkins University School of, Medicine, Baltimore, Maryland 21224, USA.
Clin Exp Allergy. 2001 Sep;31(9):1369-77. doi: 10.1046/j.1365-2222.2001.01130.x.
Desloratadine is a non-sedating, clinically effective, anti-allergic therapy that has been shown to exhibit anti-inflammatory properties that extend beyond its ability to antagonize histamine at H(1)-receptor sites. This latter effect has been shown in vitro to be both IgE-dependent and -independent.
In this study, we addressed the ability of desloratadine to inhibit the in vitro generation of interleukin (IL)-4 and IL-13 from human basophils while concurrently comparing its efficacy in preventing mediator release by these cells.
Basophil-enriched suspensions were treated with various concentrations of desloratadine for 15 min before stimulating with either anti-IgE antibody, calcium ionophore, IL-3 or phorbol ester. Histamine (fluorimetry), LTC(4) (RIA) and IL-4 (ELISA) were all assayed using the same 4-h culture supernatants. IL-13 (ELISA) was measured in supernatants harvested after 20 h incubation. IL-4 mRNA expression (dilutional RT-PCR) was also examined.
Desloratadine was found to be nearly six-seven times more potent in preventing the secretion of IL-4 and IL-13 induced by anti-IgE than it was at inhibiting the release of histamine and LTC(4). These cytokines were equally inhibited by desloratadine following activation with ionomycin despite the lack of an effect on the histamine induced with ionomycin. Desloratadine had a lesser effect regarding inhibition of the IL-13 secreted in response to IL-3 and PMA. There was no evidence that desloratadine mediated its inhibitory effects by causing decreased cell viability. Finally, IL-4 mRNA accumulation was remarkably inhibited, by as much as 80%, following pretreatment with desloratadine.
While capable of inhibiting histamine and LTC(4) release by human basophils, desloratadine is more effective at targeting the signals regulating IL-4 and IL-13 generation in these cells. This inhibitory effect on cytokine generation provides additional evidence that this antihistamine exerts anti-inflammatory properties.
地氯雷他定是一种无镇静作用、临床有效的抗过敏疗法,已显示出具有抗炎特性,其抗炎作用超出了它在H(1)受体位点拮抗组胺的能力。后一种作用在体外已显示出既依赖IgE又不依赖IgE。
在本研究中,我们探讨了地氯雷他定抑制人嗜碱性粒细胞体外产生白细胞介素(IL)-4和IL-13的能力,同时比较其预防这些细胞释放介质的效果。
用不同浓度的地氯雷他定处理富含嗜碱性粒细胞的悬液15分钟,然后用抗IgE抗体、钙离子载体、IL-3或佛波酯刺激。组胺(荧光法)、LTC(4)(放射免疫分析法)和IL-4(酶联免疫吸附测定法)均使用相同的4小时培养上清液进行检测。IL-13(酶联免疫吸附测定法)在孵育20小时后收获的上清液中进行测定。还检测了IL-4 mRNA表达(稀释逆转录聚合酶链反应)。
发现地氯雷他定在预防抗IgE诱导的IL-4和IL-13分泌方面的效力比抑制组胺和LTC(4)释放的效力高近6至7倍。在用离子霉素激活后,地氯雷他定对这些细胞因子的抑制作用相同,尽管它对离子霉素诱导的组胺没有作用。地氯雷他定对IL-3和佛波醇酯诱导分泌的IL-13的抑制作用较小。没有证据表明地氯雷他定通过降低细胞活力来介导其抑制作用。最后,用地氯雷他定预处理后,IL-4 mRNA积累受到显著抑制,高达80%。
虽然地氯雷他定能够抑制人嗜碱性粒细胞释放组胺和LTC(4),但它在靶向调节这些细胞中IL-4和IL-13生成的信号方面更有效。这种对细胞因子生成的抑制作用为这种抗组胺药发挥抗炎特性提供了额外证据。